ABSTRACT
A rational approach that may be applied to a broad class of enzyme-catalyzed reactions to design enzyme inhibitors affords a powerful strategy, facilitating the development of drugs and/or molecular probes of enzyme mechanisms. A strategy for the development of substrate-product analogues (SPAs) as inhibitors of racemases and epimerases is elaborated using isoleucine 2-epimerase from Lactobacillus buchneri (LbIleE) as a model enzyme. LbIleE catalyzes the PLP-dependent, reversible, racemization or epimerization of nonpolar amino acids at the C-2 position. The enzyme plays an important role in the biosynthesis of branched-chain d-amino acids and is a potential target for the development of antimicrobial agents. 3-Ethyl-3-methyl-l-norvaline (Ki = 2.9 ± 0.2 mM) and 3-ethyl-3-methyl-d-norvaline (Ki = 1.5 ± 0.2 mM) were designed as SPAs based on the movement of the sec-butyl side chain of the substrate l-Ile during catalysis, and were competitive inhibitors with binding affinities exceeding that of l-Ile by 1.3- and 2.5-fold, respectively. Surprisingly, these compounds were not substrates, but the corresponding compounds lacking the 3-methyl group were substrates. Unlike serine, glutamate, and proline racemases, which exhibit stringent steric requirements at their active sites, the active site of LbIleE was amenable to binding bulky SPAs. Moreover, LbIleE bound the SPA 2,2-di-n-butylglycine (Ki = 11.0 ± 0.2 mM) as a competitive inhibitor, indicating that the hydrophobic binding pocket at the active site was sufficiently plastic to tolerate gem-dialkyl substitution at the α-carbon of an amino acid. Overall, these results reveal that amino acid racemases/epimerases are amenable to inhibition by SPAs provided that they possess a capacious active site.
Subject(s)
Drug Design , Enzyme Inhibitors/pharmacology , Glycine/pharmacology , Isoleucine/antagonists & inhibitors , Lactobacillus/enzymology , Racemases and Epimerases/antagonists & inhibitors , Valine/analogs & derivatives , Binding Sites/drug effects , Biocatalysis/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Glycine/analogs & derivatives , Glycine/chemistry , Isoleucine/metabolism , Models, Molecular , Molecular Conformation , Racemases and Epimerases/metabolism , Substrate Specificity , Valine/chemical synthesis , Valine/chemistry , Valine/pharmacologyABSTRACT
GABAA receptors in cerebellar granule cells are unique in expressing a subtype containing the alpha6 subunit. This receptor subtype has high affinity for GABA and produces a degree of tonic inhibition on cerebellar granule cells, modulating the firing of these cells via spillover of GABA from GABAergic synapses. This receptor subtype also has selective affinity for the diuretic furosemide over receptors containing other alpha-subunits. Furosemide exhibits approximately 100-fold selectivity for alpha6-containing receptors over alpha1-containing receptors. By making alpha1/alpha6 chimeras we have identified a transmembrane region (209-279) responsible for the high furosemide sensitivity of alpha6beta3gamma2s receptors. Within the alpha1 transmembrane region, a single amino acid was identified that when mutated from threonine to isoleucine, increased furosemide sensitivity by 20-fold. We demonstrate the beta-subunit selectivity of furosemide to be due to asparagine 265 in the beta2 and beta3 transmembrane-domain II similar to that observed with potentiation by the anticonvulsant loreclezole. We also show that Ile in transmembrane-domain I accounts for the increased GABA sensitivity observed at alpha6beta3gamma2s compared with alpha1beta3gamma2s receptors, but did not affect direct activation by pentobarbital or potentiation by the benzodiazepine flunitrazepam. Location of these residues within transmembrane domains leads to speculation that they may be involved in the channel-gating mechanism conferring increased receptor activation by GABA, in addition to conferring furosemide sensitivity.
Subject(s)
Diuretics/pharmacology , Furosemide/pharmacology , GABA-A Receptor Antagonists , Amino Acid Sequence , Animals , Dose-Response Relationship, Drug , Humans , Isoleucine/antagonists & inhibitors , Isoleucine/genetics , Isoleucine/metabolism , Molecular Sequence Data , Oocytes , Point Mutation , Receptors, GABA-A/genetics , Receptors, GABA-A/metabolism , Recombinant Fusion Proteins/antagonists & inhibitors , Recombinant Fusion Proteins/genetics , Sequence Homology, Amino Acid , Xenopus laevisABSTRACT
Numerous abnormal metabolites were identified in large amounts in the urine of hypoglycin-treated rats using capillary gas chromatography/mass spectrometry-computer analysis. These metabolites are not detectable in significant amounts in normal rats' urine. Ten of them have not been previously associated with hypoglycin administration: these are several hydroxy compounds, including those from the valine and isoleucine pathways, 2-oxo-adipic acid, n-butyrylglycine and isovaleryl glucuronide. These results indicate that the pathways of isoleucine and valine metabolism are inhibited at their respective acyl-CoA dehydrogenation steps, as is the case for fatty acid, leucine and lysine metabolism, as previously shown. The mass spectra of the trimethylsilyl derivatives of cis, cis-4,7-decadiene-1,10-dioic, cis-4-decene-1,10-dioic, cis-4-octene-1,8-dioic acids, and (methylenecyclopropyl)acetylglycine, which were previously identified using nuclear magnetic resonance and oxidative cleavage or acid hydrolysis, are presented for the first time.
Subject(s)
Cyclopropanes/pharmacology , Dicarboxylic Acids/urine , Hydroxy Acids/urine , Hypoglycins/pharmacology , Isoleucine/antagonists & inhibitors , Valine/antagonists & inhibitors , Adipates/urine , Animals , Gas Chromatography-Mass Spectrometry , Glucuronates/urine , Glucuronic Acid , Glucuronidase , Glycine/analogs & derivatives , Glycine/urine , Male , Rats , Rats, Inbred Strains , Valerates/urineSubject(s)
Amino Acids, Branched-Chain/metabolism , 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) , Amino Acids, Branched-Chain/antagonists & inhibitors , Amino Acids, Branched-Chain/blood , Animals , Chemical Phenomena , Chemistry, Physical , Cytosol/enzymology , Dietary Proteins/pharmacology , Enzyme Activation/drug effects , Hemiterpenes , Hormones/pharmacology , Humans , Isoenzymes/metabolism , Isoleucine/antagonists & inhibitors , Keto Acids/blood , Keto Acids/metabolism , Ketone Oxidoreductases/metabolism , Kinetics , Leucine/pharmacology , Liver/metabolism , Mitochondria/enzymology , Multienzyme Complexes/metabolism , Nitrogen/metabolism , Oxidation-Reduction , Substrate Specificity , Tissue Distribution , Transaminases/metabolism , Valine/antagonists & inhibitorsABSTRACT
The inhibition of growth of the K-12 strain of Escherichia coli by glycyl-l-leucine observed originally by Simmonds and co-workers was investigated. The inhibition was reversed by isoleucine and those precursors of isoleucine beyond threonine in the biosynthetic pathway. Threonine reversed the inhibition poorly. With heavy cell suspensions, the inhibition was transient: the onset of growth followed the disappearance of the dipeptide from the medium and the appearance of glycine and leucine. Glycyl-leucine was shown to be an inhibitor of threonine deaminase (EC 4.2.1.16 l-threonine hydro-lyase [deaminating]). One kind of glycyl-leucine-resistant mutant had a threonine deaminase that was resistant to isoleucine and glycyl-leucine inhibition. The pattern of glycyl-leucine inhibition is compared with those of inhibition by isoleucine and by the weaker inhibitors leucine and valine.
Subject(s)
Dipeptides/pharmacology , Escherichia coli/metabolism , Isoleucine/biosynthesis , Valine/biosynthesis , Acylation , Cell-Free System , Chloramphenicol/pharmacology , Culture Media , Drug Resistance, Microbial , Escherichia coli/drug effects , Escherichia coli/enzymology , Escherichia coli/growth & development , Glycine/pharmacology , Hydro-Lyases/metabolism , Isoleucine/antagonists & inhibitors , Isoleucine/pharmacology , Leucine/pharmacology , Lyases/metabolism , Mutation , Operon , Pyruvates , Rifampin/pharmacology , Threonine , Valine/pharmacologySubject(s)
Anti-Bacterial Agents/pharmacology , Bacillus subtilis/drug effects , Drug Resistance, Microbial , Glyoxylates/antagonists & inhibitors , Isoleucine/metabolism , Bacillus subtilis/enzymology , Bacillus subtilis/growth & development , Bacillus subtilis/metabolism , Deamination , Glyoxylates/metabolism , Hydro-Lyases/analysis , Isoleucine/antagonists & inhibitors , Mutation , ThreonineABSTRACT
Isoleucine hydroxamate (Ile.Hdx) was found to inhibit the growth of Serratia marcescens and to antagonize isoleucine. At a low concentration of Ile.Hdx, at which the growth of the wild strain was completely inhibited, the growth of an isoleucine auxotroph was not inhibited in the medium containing a limiting amount of d-threonine as the isoleucine source. At a higher concentration, this antagonist exhibited a considerable inhibitory effect on the growth of the auxotroph. Ile.Hdx showed the same inhibitory effect as isoleucine on l-threonine dehydratase activity at the concentrations 10 times those of isoleucine. Ile.Hdx caused also derepression of isoleucine-valine biosynthetic enzymes and the derepression was overcome by isoleucine. These results indicate the Ile.Hdx causes growth inhibition by its effects on isoleucine metabolism.